Atomoxetine pharmacogenetics: Associations with pharmacokinetics, treatment response and tolerability

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations

Abstract

Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder and is predominantly metabolized by the CYP2D6 enzyme. Differences in pharmacokinetic parameters as well as clinical treatment outcomes across CYP2D6 genotype groups have resulted in dosing recommendations within the product label, but clinical studies supporting the use of genotype guided dosing are currently lacking. Furthermore, pharmacokinetic and clinical studies have primarily focused on extensive as compared with poor metabolizers, with little information known about other metabolizer categories as well as genes involved in the pharmacodynamics of atomoxetine. This review describes the pharmacogenetic associations with atomoxetine pharmacokinetics, treatment response and tolerability with considerations for the clinical utility of this information.

Original languageEnglish (US)
Pages (from-to)1513-1520
Number of pages8
JournalPharmacogenomics
Volume16
Issue number13
DOIs
StatePublished - Aug 1 2015

Bibliographical note

Publisher Copyright:
© 2015 Future Medicine Ltd.

Keywords

  • ADHD
  • CYP2D6
  • atomoxetine
  • pharmacogenetics

Fingerprint

Dive into the research topics of 'Atomoxetine pharmacogenetics: Associations with pharmacokinetics, treatment response and tolerability'. Together they form a unique fingerprint.

Cite this